Drugs / αCD22-TCRz-41BB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02903810 | Sep 2016 → Dec 2018 | hematopoietic and lymphoid cell neoplasm | Xuzhou Medical University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | αCD22-TCRz-41BB | “All subjects will be infused with αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T cells in equal number” NCT02903810 ↗ |
| Modality | Cell therapy | “CAR-T cells” NCT02903810 ↗ |